MICOT PHARMA-B Shares Gain Over 3% Following Milestone in Stroke Drug Trial

Stock News07-07 11:50

Shares of MICOT PHARMA-B (02335) advanced more than 3% in morning trading. At the time of writing, the stock was up 3.53% to HK$39.84, with a turnover of HK$11.28 million.

The upward movement follows a company announcement regarding its self-developed drug candidate, MT1002, for treating acute ischemic stroke. The announcement stated that the first patient has been successfully enrolled in the Ib/II phase clinical trial for the drug. This milestone signifies the formal commencement of the substantive execution phase for this key registration study.

Details of the Clinical Trial Program

The Ib/II phase clinical trial is structured in two parts. The first part is a multicenter clinical study designed to evaluate the safety, efficacy, and pharmacokinetic profile of MT1002 in patients with acute ischemic stroke. The second part is a multicenter, randomized, standard-of-care controlled clinical study aimed at assessing the safety and efficacy of MT1002 in the same patient population.

The enrollment of the first patient, as announced, pertains specifically to the initial phase of this Ib/II stage trial.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1102075450?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-07 11:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1102075450","market":"sh","top_or_hot":-1,"title":"MICOT PHARMA-B Shares Gain Over 3% Following Milestone in Stroke Drug Trial","media":"Stock News","content":"<p><br><br>\nShares of <b>MICOT PHARMA-B</b> (<b>02335</b>) advanced more than 3% in morning trading. At the time of writing, the stock was up 3.53% to HK$39.84, with a turnover of HK$11.28 million.<br><br>\nThe upward movement follows a company announcement regarding its self-developed drug candidate, MT1002, for treating acute ischemic stroke. The announcement stated that the first patient has been successfully enrolled in the Ib/II phase clinical trial for the drug. This milestone signifies the formal commencement of the substantive execution phase for this key registration study.<br><br>\n<b>Details of the Clinical Trial Program</b><br><br>\nThe Ib/II phase clinical trial is structured in two parts. The first part is a multicenter clinical study designed to evaluate the safety, efficacy, and pharmacokinetic profile of MT1002 in patients with acute ischemic stroke. The second part is a multicenter, randomized, standard-of-care controlled clinical study aimed at assessing the safety and efficacy of MT1002 in the same patient population.<br><br>\nThe enrollment of the first patient, as announced, pertains specifically to the initial phase of this Ib/II stage trial.<br><br></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MICOT PHARMA-B Shares Gain Over 3% Following Milestone in Stroke Drug Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMICOT PHARMA-B Shares Gain Over 3% Following Milestone in Stroke Drug Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-07 11:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><br><br>\nShares of <b>MICOT PHARMA-B</b> (<b>02335</b>) advanced more than 3% in morning trading. At the time of writing, the stock was up 3.53% to HK$39.84, with a turnover of HK$11.28 million.<br><br>\nThe upward movement follows a company announcement regarding its self-developed drug candidate, MT1002, for treating acute ischemic stroke. The announcement stated that the first patient has been successfully enrolled in the Ib/II phase clinical trial for the drug. This milestone signifies the formal commencement of the substantive execution phase for this key registration study.<br><br>\n<b>Details of the Clinical Trial Program</b><br><br>\nThe Ib/II phase clinical trial is structured in two parts. The first part is a multicenter clinical study designed to evaluate the safety, efficacy, and pharmacokinetic profile of MT1002 in patients with acute ischemic stroke. The second part is a multicenter, randomized, standard-of-care controlled clinical study aimed at assessing the safety and efficacy of MT1002 in the same patient population.<br><br>\nThe enrollment of the first patient, as announced, pertains specifically to the initial phase of this Ib/II stage trial.<br><br></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VXUS","symbol_name":"国际股票ETF-Vanguard","start_time":0,"source_url":"","article_id":"1102075450","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1102075450","pubTimestamp":1783396221,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":" Shares of MICOT PHARMA-B (02335) advanced more than 3% in morning trading. At the time of writing, the stock was up 3.53% to HK$39.84, with a turnover of HK$11.28 million. The upward movement...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VXUS":"国际股票ETF-Vanguard","BK4585":"ETF&股票定投概念","IBBQ":"Invesco Nasdaq Biotechnology ETF","BK4588":"碎股","02335":"麦科医药-B","KCAI":"KraneShares China Alpha Index ETF","BMED":"iShares Health Innovation Active ETF"},"translate_title":"中风药物试验取得里程碑后，MICOT PHARMA-B股价上涨超过3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02335":1,"VXUS":1,"BMED":1,"KCAI":1,"IBBQ":1},"content_text":"Shares of MICOT PHARMA-B (02335) advanced more than 3% in morning trading. At the time of writing, the stock was up 3.53% to HK$39.84, with a turnover of HK$11.28 million.\nThe upward movement follows a company announcement regarding its self-developed drug candidate, MT1002, for treating acute ischemic stroke. The announcement stated that the first patient has been successfully enrolled in the Ib/II phase clinical trial for the drug. This milestone signifies the formal commencement of the substantive execution phase for this key registration study.\nDetails of the Clinical Trial Program\nThe Ib/II phase clinical trial is structured in two parts. The first part is a multicenter clinical study designed to evaluate the safety, efficacy, and pharmacokinetic profile of MT1002 in patients with acute ischemic stroke. The second part is a multicenter, randomized, standard-of-care controlled clinical study aimed at assessing the safety and efficacy of MT1002 in the same patient population.\nThe enrollment of the first patient, as announced, pertains specifically to the initial phase of this Ib/II stage trial.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1102075450","isCrawlerRequest":true}